Eskazole / Zentel

Natpar

Human medicines European public assessment report (EPAR): Qezzaqar, catequentinib, Status: Opinion

Good pharmacovigilance practices (GVP)

Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with revision 2 of Module III on pharmacovigilance inspections

Agenda of the CAT meeting 9-11 September 2026

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Date of authorisation: 13/07/2011, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Sivextro, tedizolid phosphate, Date of authorisation: 23/03/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Suliqua, insulin glargine,lixisenatide, Date of authorisation: 11/01/2017, Revision: 16, Status: Authorised